Narrative review / 2021
A review indicates oral nicotinamide may reduce the incidence of actinic keratoses and non-melanoma skin cancers, though intake must be chronic.
This comprehensive review evaluated the role of nicotinamide (NAM), a water-soluble form of vitamin B3, in skin cancer chemoprevention. In the cited Phase III double-blinded placebo-controlled ONTRAC study, the incidence of actinic keratoses and non-melanoma skin cancers was lower in the nicotinamide group than in the placebo group. Additional studies highlighted efficacy in transplant patients and individuals in arsenic-contaminated regions. However, the authors note that NAM intake must be maintained chronically because its efficacy appears to vanish rapidly.
- Study type
- Comprehensive narrative review
- Who was studied
- Human populations, including transplant patients and inhabitants in arsenic areas
- What was measured
- Chemoprevention of skin cancers and actinic keratoses
THE PAPER
Oral nicotinamide: The role in skin cancer chemoprevention.
Giacalone S, Spigariolo CB, Bortoluzzi P, Nazzaro G. Dermatol Ther, 2021.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.